Masimo Co. (NASDAQ:MASI) Given Average Rating of “Moderate Buy” by Analysts

Shares of Masimo Co. (NASDAQ:MASI) have been assigned a consensus rating of “Moderate Buy” from the seven brokerages that are currently covering the stock, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $143.57.

MASI has been the topic of a number of research reports. Needham & Company LLC restated a “hold” rating on shares of Masimo in a research report on Tuesday, July 9th. BTIG Research raised their price target on Masimo from $145.00 to $166.00 and gave the company a “buy” rating in a research report on Monday, March 25th. Stifel Nicolaus upgraded Masimo from a “hold” rating to a “buy” rating and raised their price target for the company from $148.00 to $170.00 in a research report on Monday, April 15th. Wells Fargo & Company upgraded Masimo from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $117.00 to $160.00 in a report on Monday, March 25th. Finally, StockNews.com upgraded Masimo from a “sell” rating to a “hold” rating in a report on Friday, March 29th.

Masimo Trading Up 0.6 %

Shares of MASI stock opened at $111.96 on Wednesday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.31 and a current ratio of 2.31. Masimo has a 52-week low of $75.22 and a 52-week high of $153.93. The company has a market capitalization of $5.95 billion, a PE ratio of 76.16 and a beta of 0.97. The business’s fifty day moving average is $124.44 and its 200 day moving average is $128.95.

Masimo (NASDAQ:MASI) last issued its quarterly earnings data on Tuesday, May 7th. The medical equipment provider reported $0.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.71 by $0.06. Masimo had a return on equity of 13.26% and a net margin of 4.01%. The company had revenue of $492.80 million for the quarter, compared to the consensus estimate of $487.70 million. During the same quarter last year, the business posted $0.87 earnings per share. The firm’s revenue was down 12.8% compared to the same quarter last year. On average, equities research analysts anticipate that Masimo will post 3.63 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Craig B. Reynolds sold 40,000 shares of the firm’s stock in a transaction dated Friday, April 26th. The stock was sold at an average price of $136.17, for a total value of $5,446,800.00. Following the sale, the director now directly owns 7,406 shares of the company’s stock, valued at $1,008,475.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 9.70% of the stock is owned by insiders.

Institutional Trading of Masimo

Several large investors have recently modified their holdings of MASI. Bamco Inc. NY bought a new stake in shares of Masimo in the first quarter worth about $50,781,000. Schroder Investment Management Group boosted its position in Masimo by 59.6% during the 4th quarter. Schroder Investment Management Group now owns 877,539 shares of the medical equipment provider’s stock valued at $102,856,000 after acquiring an additional 327,863 shares in the last quarter. Westfield Capital Management Co. LP boosted its position in Masimo by 35.6% during the 4th quarter. Westfield Capital Management Co. LP now owns 818,476 shares of the medical equipment provider’s stock valued at $95,934,000 after acquiring an additional 214,795 shares in the last quarter. Farallon Capital Management LLC boosted its position in Masimo by 13.6% during the 1st quarter. Farallon Capital Management LLC now owns 1,489,563 shares of the medical equipment provider’s stock valued at $218,742,000 after acquiring an additional 177,914 shares in the last quarter. Finally, Hudson Bay Capital Management LP bought a new stake in Masimo during the 3rd quarter valued at approximately $12,497,000. 85.96% of the stock is owned by institutional investors.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.